Brain Health Therapeutics

Brain Health Therapeutics

Brain Health Therapeutics, Developer of Novel Patented Technologies to Improve Outcomes for Alzheimer’s Patients, Announces New Team

SAN FRANCISCO, Oct. 26, 2017 /PRNewswire/ — Brain Health Therapeutics, Inc., which is developing novel patented technologies to improve outcomes for neurological disorder patients today announced the appointment of Dr. Nick Poulios as Chief Executive Officer of the company.

Dr. Poulios is a business executive, editor, author, and market access expert. He brings to Brain Health Therapeutics more than two decades of executive leadership and international experience in biotechnology, pharmaceutical, diagnostics and global health, as well as a global network of relationships within the pharma/diagnostics community and industry that will enhance the company’s ability to pursue partnerships and financings.

Dr. Poulios was VP of Market Access, Strategic Pricing & Reimbursement for Elan Pharmaceuticals in charge of Tysabri for MS (Multiple Sclerosis), Bapineuzumab (Alzheimer’s) and Prialt (Chronic Pain). Most recently, Dr. Poulios was Head of Medical Outcomes Reimbursement & Economics at Roche Molecular Diagnostics. He has had similar positions at Roche Pharma, Baxter Bioscience and Gen-Prob Molecular Diagnostics.

Brain Health Therapeutics has partnered with a major US university which through NIH funded Research has uncovered a technology that combines two FDA approved drugs that are shown to be effective in altering disease progression in Alzheimer’s and other neurodegenerative diseases such as MS and Parkinson’s.

“Combining these two drugs through our patented formulation eliminates the side effects of the first drug which vastly reduce its use, while retaining its remarkably beneficial effects produced by slowing amyloid protein plaque growth believed to be the cause of the disease,” said Dr. Poulios, CEO of Brain Health Therapeutics.

A preclinical study published in the Journal of Alzheimer’s Disease found that very small doses of tetrahydrocannabinol (THC), can slow the production of beta- amyloid proteins, thought to be a key contributor to the progression of Alzheimer’s. The problem is that long term use of THC can produce side effects, such as adverse physical, mental, emotional, and cognitive changes.

“We are moving rapidly to begin pre-clinical development of our proprietary therapy,” said Dr. Benjamin Hoehn, MD, PhD who recently joined Brain Health Therapeutics as Chief Medical Officer. Most recently, Dr. Hoehn, was the CMO for J&J’s Codman Neuro Franchise and continues to make vast contributions to the rapidly expanding fields of neuroscience, neurosurgery, and healthcare.

About Brain Health Therapeutics
Brain Health Therapeutics is dedicated to the development and commercialization of critical care products with a focus on neurology, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. The company seeks to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, it seeks to reduce the risks associated with pharmaceutical product development and regulatory requirements. The company focuses on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches.

For more information, go to: